# A Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimab

Source: https://onco.cc/trials/nct06513221/  
OnCo record `nct06513221` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in colorectal cancer, run by Fudan University, not yet recruiting.

## Summary

A Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimab is a phase 2, interventional study registered as NCT06513221 by Fudan University, with a registry enrolment figure of 100 participants, started 2024-07-25 and due to reach its primary completion in 2026-04-01. Interventions recorded: Chemotherapy, Bevacizumab, Adebrelimab. Conditions listed: Metastatic Colorectal Cancer. Primary outcome: Objective Response Rate. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06513221
- Phase: 2
- Setting: A Prospective, Multi-arm, Phase II Clinical Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimab Under the Guidance of Transcriptome Profiling.
- Sponsor: Fudan University
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT06513221: https://clinicaltrials.gov/study/NCT06513221

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06513221.json